Author

R. Elliott

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Microbiology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

A. Melcher· 2 shared A. Rullan· 2 shared C. Chan· 2 shared C. J. Lord· 2 shared E. Appleton· 2 shared E. C. Patin· 2 shared J. Choudhary· 2 shared J. Wright· 2 shared

Activity by Year

2017-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Melcher

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

PARP inhibitors enhance reovirus-mediated cell killing through the death-inducing signaling complex (DISC) with an associated NF-kappa B-regulated immune response.

J. Kyula-Currie, V. Roulstone, J. Wright, F. Butera, A. Legrand, R. Elliott, M. McLaughlin, G. Bozhanova, D. B. Krastev, S. Pettitt, T. Tenev, M. T. B. Dillon, S. Foo, E. C. Patin, V. Jennings, , K. J. Harrington

This paper identifies PARP inhibitors as sensitizers for oncolytic reovirus by enhancing DISC-mediated apoptosis and NF-kappa B-driven immune responses.

bioRxiv · Dec 21, 2023 · PreprintCancer Biology

CDK4/6 inhibition and dsRNA sensor agonism co-operate to enhance anti-cancer effects through ER stress and immune modulation of tumour cells

V. Roulstone, J. Kyula, J. Wright, L. Yu, A. Barreiro Alonso, M. Melake, J. Choudhary, R. Elliott, C. J. Lord, D. Mansfield, N. Matthews, R. Chauhan, V. Jennings, C. Chan, H. Baldock, , K. J. Harrington

bioRxiv · Sep 28, 2022 · PreprintCancer Biology

Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide are Potent TMEM16A Antagonists that Fully Bronchodilate Airways

K. Miner, K. Labitzke, B. Liu, P. Wang, K. Henckels, K. Gaida, R. Elliott, J. J. Chen, L. Liu, A. Leith, E. Trueblood, K. Hensley, X.-Z. Xia, O. Homann, B. Bennett, , J. K. Sullivan

This paper identifies niclosamide and nitazoxanide as potent TMEM16A antagonists that fully bronchodilate airways, offering new treatment options for severe asthma and COPD.

bioRxiv · Nov 14, 2018Physiology

Mouse hepatitis virus nsp14 exoribonuclease activity is required for resistance to innate immunity

J. B. Case, Y. Li, R. Elliott, X. Lu, K. W. Graepel, N. R. Sexton, E. C. Smith, S. R. Weiss, M. R. Denison

This study shows that MHV nsp14 exoribonuclease activity is necessary for resisting innate immunity by affecting viral RNA and modifications.

bioRxiv · Aug 29, 2017Microbiology